Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(167 products)
- Bcr-Abl(118 products)
- EGFR(581 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2382 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
KIT/PDGFRA-IN-1
KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.Formula:C26H18F3N5O2Color and Shape:SolidMolecular weight:489.449AST5902
CAS:AST5902 is the active metabolite of Alflutinib.Formula:C27H29F3N8O2Purity:98%Color and Shape:SolidMolecular weight:554.57MPT0B390
CAS:MPT0B390 is an inhibitor of HDAC and a TIMP3 inducer inhibiting tumor growth, metastasis, and angiogenesis.Formula:C17H17N3O5SPurity:99.4%Color and Shape:SolidMolecular weight:375.4AT-533
CAS:AT-533 inhibits Hsp90, HSV, hinders HIF-1α/VEGF/VEGFR-2, Erk1/2, FAK, Akt/mTOR/p70S6K, and blocks tumor growth, angiogenesis, and HUVEC activities.Formula:C23H30N4O3Purity:99.67%Color and Shape:SoildMolecular weight:410.51Ref: TM-T67836
1mg37.00€5mg82.00€10mg116.00€25mg207.00€50mg309.00€100mg447.00€200mg600.00€1mL*10mM (DMSO)86.00€PROTAC FLT3/CDK9 degrader-1
Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.Formula:C48H62N12O7Color and Shape:SolidMolecular weight:919.08EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99PACAP-38 (31-38), human, mouse, rat TFA
PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.Formula:C49H84F3N17O13Purity:98%Color and Shape:SolidMolecular weight:1176.29Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurity:98%Color and Shape:Odour SolidWDR5 ligand 2
CAS:WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.Formula:C29H31F3N4O4Color and Shape:SolidMolecular weight:556.576hCA/VEGFR-2-IN-4
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/Formula:C22H23FN6O5SPurity:98%Color and Shape:SolidMolecular weight:502.52PROTAC EGFR degrader 7
Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.Formula:C46H48N10O6Color and Shape:SolidMolecular weight:836.94VSLRGDTRG
CAS:VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.Formula:C38H69N15O14Color and Shape:SolidMolecular weight:960.047INCB-000928
CAS:Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.
Formula:C30H38N4O3Purity:98.93%Color and Shape:SolidMolecular weight:502.65DD0-2363
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.Formula:C36H36ClFN6O4Color and Shape:SolidMolecular weight:671.16PROTAC EGFR degrader 4
CAS:PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).Formula:C55H70N12O4SColor and Shape:SolidMolecular weight:995.29GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9MLK3-IN-1
MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.Formula:C20H16F6N4O2SColor and Shape:SolidMolecular weight:490.422SNIPER(ABL)-015
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5Formula:C58H70F3N9O9Purity:98%Color and Shape:SolidMolecular weight:1094.23Sorafenib-d4
CAS:Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.Formula:C21H16ClF3N4O3Purity:98%Color and Shape:SolidMolecular weight:468.85HIF-1 inhibitor-4
CAS:HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM.Formula:C18H19IN2O2Purity:99.26%Color and Shape:SolidMolecular weight:422.26ALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Formula:C24H30ClN6O2PColor and Shape:SolidMolecular weight:500.97GSK143
CAS:GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.Formula:C17H22N6O2Color and Shape:SolidMolecular weight:342.403Syk Inhibitor II hydrochloride
CAS:Syk signaling is key in lupus. Syk inhibitors reduce inflammation and sepsis severity in FcgRIIb-/- mice, lowering cytokines and organ damage.Formula:C14H16ClF3N6OPurity:99.05%Color and Shape:SolidMolecular weight:376.77Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formula:C36H35FN6O10Color and Shape:SolidMolecular weight:730.696PROTAC FGFR1 degrader-1
PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.Formula:C46H54N8O8Color and Shape:SolidMolecular weight:846.972-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Formula:C21H20Cl2FN5O2Purity:98%Color and Shape:SolidMolecular weight:464.32DB1113
CAS:DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.Formula:C59H68F3N13O6SColor and Shape:SolidMolecular weight:1144.31PROTAC BCR-ABL1 ligand 1
CAS:GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.Formula:C17H12F3N3O2Color and Shape:SoildMolecular weight:347.29SNIPER(ABL)-033
CAS:SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL proteinFormula:C61H73F3N10O9S2Purity:98%Color and Shape:SolidMolecular weight:1211.42PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formula:C46H50F3N13O8Purity:98%Color and Shape:SolidMolecular weight:969.97ABP-102
ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.Color and Shape:Odour LiquidALK-IN-9
CAS:ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.Formula:C20H21FN6O3Color and Shape:SolidMolecular weight:412.425VEGFR-2-IN-64
VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.Formula:C72H123N9O6Color and Shape:SolidMolecular weight:1210.8BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532Emodic acid
CAS:Emodic acid is a useful organic compound for research related to life sciences. The catalog number is T124807 and the CAS number is 478-45-5.Formula:C15H8O7Color and Shape:SolidMolecular weight:300.222EGFR-IN-78
EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.Formula:C23H32BrN7O2SPurity:98%Color and Shape:SolidMolecular weight:550.51Verucopeptin
CAS:Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Formula:C43H73N7O13Color and Shape:SolidMolecular weight:896.08TYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Formula:C25H18N4O3Purity:98%Color and Shape:SolidMolecular weight:422.44SI-2
CAS:SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.Formula:C15H15N5Purity:98.4%Color and Shape:SolidMolecular weight:265.31Ref: TM-T28773
1mg358.00€5mg873.00€10mg1,161.00€25mg1,755.00€50mg2,358.00€100mg3,177.00€1mL*10mM (DMSO)800.00€MTX-241F
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.Formula:C20H14ClFN6Purity:98%Color and Shape:SolidMolecular weight:392.827-Hydroxyneolamellarin A
CAS:7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Formula:C24H19NO5Color and Shape:SolidMolecular weight:401.41FLT3 Ligand-Linker Conjugate 1
CAS:FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Formula:C29H34N6O4S2Color and Shape:SolidMolecular weight:594.748HER2/neu (654-662) GP2
CAS:Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.Formula:C42H77N9O11Purity:98%Color and Shape:SolidMolecular weight:884.11TL13-110
CAS:Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Formula:C49H62ClN9O9SColor and Shape:SolidMolecular weight:988.59JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7Scr-IN-1
Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.Formula:C26H16ClF3N2O3Color and Shape:SolidMolecular weight:496.87PROTAC EGFR degrader 8
CAS:PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.Formula:C40H46ClN11O5Purity:98%Color and Shape:SolidMolecular weight:796.32IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Color and Shape:Odour LiquidVEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Formula:C29H27N9OPurity:98%Color and Shape:SolidMolecular weight:517.58SPP-037
SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.Formula:C36H50ClN3O9SColor and Shape:SolidMolecular weight:735.29563DSPE-PEG2000-A7R
DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Color and Shape:Odour SolidIBI-334
IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.Color and Shape:Odour LiquidAnticancer agent 271
Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.Color and Shape:Odour SolidPST3.1a
CAS:PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).Formula:C32H33O6PColor and Shape:SolidMolecular weight:544.57JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.161EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formula:C50H55ClFN5O5Color and Shape:SolidMolecular weight:860.45ML228
CAS:ML228 activates HIF pathway and VEGF, with EC50 of 1μM, effective in vitro.Formula:C27H21N5Purity:99.54%Color and Shape:SolidMolecular weight:415.49JAK-2/3-IN-1
CAS:JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.Formula:C20H12ClN3OColor and Shape:SolidMolecular weight:345.79BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508EGFR/COX-2-IN-1
EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.Formula:C20H17FN6O2S2Color and Shape:SolidMolecular weight:456.52Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.Formula:C88H138N20O34P2Purity:98%Color and Shape:SolidMolecular weight:2082.1Varlitinib Tosylate
CAS:Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formula:C36H35ClN6O8S3Purity:98%Color and Shape:SolidMolecular weight:811.34TYD-68
TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.Color and Shape:Odour SolidLewis y tetrasaccharide
CAS:Lewis Y tetrasaccharide, a derivative of Lewis X, is an antigen linked to ovarian cancer metastasis and bad prognosis.Formula:C26H45NO19Color and Shape:SolidMolecular weight:675.63BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.Formula:C28H29FN6O2SColor and Shape:SolidMolecular weight:532.63SIAIS178
CAS:SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formula:C50H62ClN11O6S2Purity:98.07%Color and Shape:SolidMolecular weight:1012.68Ref: TM-T12907
1mg152.00€5mg356.00€10mg485.00€25mg888.00€50mg1,431.00€100mg2,052.00€200mg2,673.00€1mL*10mM (DMSO)393.00€VnP-16
VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activatesFormula:C82H112N20O17Purity:98%Color and Shape:SolidMolecular weight:1649.89Amuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formula:C23H22ClN5O3SPurity:98%Color and Shape:SolidMolecular weight:483.97Antifibrotic agent 1
Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.Formula:C27H23ClN6O2Color and Shape:SolidMolecular weight:498.1571Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Formula:C33H34N4O3Color and Shape:SolidMolecular weight:534.648PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formula:C22H22FN5O2Color and Shape:SolidMolecular weight:407.44SJF 1528
CAS:Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).Formula:C55H57ClFN7O8SColor and Shape:SolidMolecular weight:1030.61Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Purity:98%Color and Shape:Odour SolidEGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Formula:C22H16N4OSColor and Shape:SolidMolecular weight:384.45Pomalidomide-C5-Dovitinib
CAS:Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC that links Pomalidomide and Dovitinib via a CRBN connector, exhibiting potent antiproliferative activity inFormula:C39H38FN9O6Purity:98%Color and Shape:SolidMolecular weight:747.77AD57
CAS:AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Formula:C22H20F3N7OPurity:99.05%Color and Shape:SoildMolecular weight:455.44MS9427
CAS:MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.Formula:C48H58ClFN8O12Color and Shape:SolidMolecular weight:993.47VSLRGDTRG acetate
VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.Color and Shape:Odour SolidBevasiranib sodium
CAS:Bevasiranib sodium, a siRNA, silences genes for VEGF, key in CNV pathogenesis and wet AMD precursor.Color and Shape:SolidOK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Formula:C42H62N14O9Purity:98%Color and Shape:SolidMolecular weight:907.03Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formula:C63H107N19O20S2Purity:98%Color and Shape:SolidMolecular weight:1514.77VEGFR-2-IN-36
VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstratedFormula:C24H23N7O5Purity:98%Color and Shape:SolidMolecular weight:489.48Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS:Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formula:C51H65N17O19P2S2·xC6H15NColor and Shape:SolidMolecular weight:1447.44DSPE-PEG1000-A7R
DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Color and Shape:Odour SolidAbl Cytosolic Substrate
CAS:Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Formula:C64H101N15O16Purity:98%Color and Shape:SolidMolecular weight:1336.58PROTAC VEGFR-2 degrader-1
CAS:PROTAC VEGFR-2 degrader-1 shows minimal VEGFR-2 inhibition & low anti-proliferative effect on EA.hy926 cells.Formula:C52H61N9O6SColor and Shape:SolidMolecular weight:940.163-Methylthienyl-carbonyl-JNJ-7706621
CAS:Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Formula:C14H14N6O3S2Color and Shape:SolidMolecular weight:378.43FAK-IN-1
CAS:FAK-IN-1 is a FAK inhibitor with anticancer activities (WO2020231726 (Example 27)).Formula:C24H26F3N7O4SColor and Shape:SolidMolecular weight:565.57EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Formula:C27H31N3O2Color and Shape:SolidMolecular weight:429.24163DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163EGFR-IN-144
EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.Formula:C20H17Cl2N3O3Color and Shape:SolidMolecular weight:418.273AZ14240475
AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.Formula:C23H15ClF2N6O2Color and Shape:SolidMolecular weight:480.854EGFR-IN-151
EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.Color and Shape:Odour SolidGefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Formula:C22H24ClFN4O41·5HClColor and Shape:SolidMolecular weight:517.59BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Color and Shape:SolidMolecular weight:1082.224PROTAC BTK Degrader-6
CAS:PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFormula:C45H47N11O6Purity:98%Color and Shape:SolidMolecular weight:837.92HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Color and Shape:Odour SolidCS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formula:C45H53F7N12O9Color and Shape:SolidMolecular weight:1038.39467DSPE-PEG2000-GE11
DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.Color and Shape:Odour Solid
